Table 5.
Overall survival in the phase III studies of eribulin by human epidermal growth factor receptor 2 (HER2) and oestrogen receptor (ER) status
| 305 (EMBRACE) [30, 55] | 301 [31, 32] | |||||
|---|---|---|---|---|---|---|
| OS (months) | HR (95 % CI) | OS (months) | HR (95 % CI) | |||
| Eribulin | TPC | Eribulin | CAP | |||
| Total | 13.1 | 10.6 | 0.81 (0.66, 0.99) | 15.9 | 14.5 | 0.88 (0.77, 1.00) |
| HER2+ | 11.3a | 9.1a | 0.76 (0.47, 1.24) | 14.3 | 17.1 | 0.97 (0.69, 1.36) |
| HER2− | 13.2a | 10.5a | 0.81 (0.64, 1.02) | 15.9 | 13.5 | 0.84 (0.72, 0.98) |
| ER+ | 13.8a | 11.4a | 0.81 (0.63, 1.04) | 18.2 | 16.8 | 0.90 (0.74, 1.09) |
| ER− | 10.2a | 7.8a | 0.78 (0.54, 1.13) | 14.4 | 10.5 | 0.78 (0.64, 0.96) |
| TN | 9.5a | 7.0a | 0.71 (0.46, 1.10) | 14.4 | 9.4 | 0.70 (0.55, 0.91) |
CAP capecitabine, ER oestrogen receptor, HER2 human epidermal growth factor receptor 2, TN triple negative, TPC treatment of physician’s choice
aValues calculated from data available from the Pharmaceuticals and Medical Devices Agency, Japan. Halaven 1 mg Rinsyo Gaiyou [55]